ELIPSE-COL: A novel ELISA test based on rational envisioned synthetic peptides for detection of SARS-CoV-2 infection in Colombia.
Arevalo, A.; Franco-Munoz, C.; Duque-Beltran, S.; Munoz-Galindo, L.; Herrera-Sepulveda, M. T.; Lozano, J. M.; Salazar, L. M.; Ospina-Martinez, M. L.; Mercado-Reyes, M.
Show abstract
BackgroundCOVID-19 pandemic caused by infection with the betacoronavirus SARS-CoV-2 is the greatest public health defiant on a global scale in the last 100 years. Governments and health Institutes face challenges during the pandemic, related to the diagnosis, mitigation, treatment, and timely detection after the epidemic peak for the prevention of new infections and the evaluation of the real impact of the COVID-19 disease in different geographic areas. To develop a valuable tool to study the seroprevalence of SARS-CoV-2 infection in Colombia, an "in-house" ELISA was achieved for the detection of IgG anti-SARS-CoV-2 antibodies in serum. MethodsThe test was standardized using an antigenic epitope "Pool" of the synthetic peptide as antigen derived from antigenic regions of the spike, nucleocapsid, envelope, and membrane structural proteins, which were designed, based on the genomic information of SARS-CoV-2 circulating in Colombia. In the ELISA standardization process, 94 positive sera were used, including sera from asymptomatic and symptomatic patients (mild and severe) and 123 negative sera, including pre-pandemic historical negatives originating from patients living in arbovirus endemic areas or patients with a history of respiratory diseases and sera from patients with a negative rRT-PCR test for SARS-CoV-2. ResultsThe in-house peptide ELIPSE-COL test showed promising performance, being able to detect reactivity in sera from asymptomatic and symptomatic patients. The sensitivity and specificity of the assay were 91.4% and 83.7% respectively. ConclusionELIPSE-COL assay was developed as an ELISA test using synthetic peptides for the study of the seroprevalence of SARS-CoV-2 infection in Colombia. SUMMARY BOXO_LIDetection of IgG anti-SARS-CoV-2 antibodies is required for the evaluation of the pandemic impact and vaccination strategies. C_LIO_LIELIPSE-COL is an in-house test based on synthetic peptides as antigen derived from antigenic regions of the spike, nucleocapsid, envelope, and membrane structural proteins. C_LIO_LIThe sensitivity and specificity of the assay were 91.4% and 83.7% respectively suggesting a promising performance. C_LIO_LIELIPSE-COL test is a valuable tool for the study of seroprevalence in Colombia. C_LI
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Scoping review of the applications of peptide microarrays on the fight against human infections. 96%
- Development And Performance Evaluation of A Rapid In-House ELISA for Retrospective Serosurveillance of SARS-CoV-2 96%
- Development and Evaluation of Two Rapid Indigenous IgG-ELISA immobilized with ACE-2 Binding Peptides for Detection Neutralizing Antibodies Against SARS-CoV-2 96%
Similar papers in this journal
- Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from plasma or fingerstick whole-blood of COVID-19 vaccinees 95%
- Antibody response to SARS-CoV2 among COVID-19 confirmed cases, and correlates with neutralizing assay in a subgroup of patients in Delhi National Capital Region, India 95%
- Surrogate virus neutralisation test based on nanoluciferase-tagged antigens to quantify inhibitory antibodies against SARS-CoV-2 and characterise Omicron-specific reactivity 94%
Similar papers in this journal
- SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications 94%
- Design and Performance Characteristics of the Elecsys Anti-SARS-CoV-2 S assay 93%
- Isolation of a nanobody specific to the PstS-1 protein and evaluation of its immunoreactivity with structural components of Mycobacterium tuberculosis granuloma 93%
Similar papers in this journal
- Antibody responses to BNT162b2 vaccination in Japan: Monitoring vaccine efficacy by measuring IgG antibodies against the receptor binding domain of SARS-CoV-2 94%
- A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR 94%
- Rapid semi-quantitative point of care diagnostic test for post vaccination antibody monitoring 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.